Recent Publications

(2019-present)

1. Broce IJ, Tan CH, Fan CC, Witoelar A, Wen N, Jansen I, Hess CP, Dillon WP, Glastonbury CM, Glymour M, Yokoyama JS, Elahi FM, Rabinovici GD, Miller BL, Mormino EC, Sperling RA, Bennett DA, McEvoy LK, Brewer JB, Feldman HH, Posthuma D, Hyman BT, Schellenberg GS, Yaffe K, Pericak-Vance M, Haines JL, Farrer LA, Mayeux R, Andreassen OA, Dale AM, Sugrue LP, Karch CM, Desikan RS: Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer’s disease. Acta Neuropathol. 2019 Feb; 137(2):209-226. Epub Nov 9 2018. Doi: 10.1007/s00401-018-1928-6 [PMID: 30413934]
2. Huisa BN, Thomas RG, Jin S, Ottersdorf T, Taylor C, Feldman HH: Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer’s Disease Clinical Trials: Potential for Confounding by Indication. J Alzheimers Dis. 2019;67 (2) 707-713 Epub Jan 8 2019;67(2).707-713. doi: 12.3233/JAD-180684 [PMID: 30636733]
3. Sano M, Zhu CW, Kaye J, Mundt JC, Thomas RG, Sun CK, Jiang Y, Donohue M, Schneider L, Egelko S, Aisen P, Feldman HH, Hayes TL, Ferris S, for the Alzheimer’s Disease Cooperative Study Investigators: A Randomized Clinical Trial to Evaluate Home-based Assessment of People over 75 Years Old. Alzheimers Dement. 2019 May 15(5) 615-624 Epub Mar 11 2019. Doi: 10.1016/j.jalz.2019.01.007 [PMID: 30872114]
4. Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohades Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylet RJ: The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. Can J Neurological Sciences. 2019 Sept 46(5) 499-511 Doi: 10.1017/cjn.2019.27 Epub 2019 Jul 16 [PMID: 31309917].
5. Kent BA, Michalik M, Marchant EG, Yau KW, Feldman HH, Mistlberger RE, Nygaard HB: Delayed daily activity and reduced NREM slow-wave power ibn the APPswe/PS1dE9 mouse model of Alzheimer’s Disease. Neurobiol Aging. 2019 Jun; 78:74-86. doi: 10.1016/j.neurobiolagin.2019.01.010. Epub 2019 Feb 14 [PMID: 30884411]
6. Qui Y, E Jacobs DM, Messer K, Salmon DP, Feldman HH: Cognitive Heterogeneity in Probable Alzheimer’s Disease: Clinical and Neuropathological Features. Neurology 2019 August 20:93 (8) e778-e790 Epub 2019 Jul 18. doi: https://doi.org/10.1212/WNL.0000000000007967 [PMID 31320469]
7. Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, and Feldman HH, Alzheimer’s Disease Cooperative Study TCAD Group: The safety and efficacy of edonerpic maleate (T-817MA) in patients with mild to moderate Alzheimer’s disease. JAMA Neurology. Epub 2019 Jul 8. doi:10.1001/jamaneurol. 2019. 1868 [PMID 31282954]
8. Cummings J, Feldman HH, Scheltens P: The “Rights” of Precision Drug Development for Alzheimer’s Disease. Alzheimers Res Ther 2019 August 31;11(1):76. doi: 10.1186/s13195-019-0529-5 [PMID 31470905]
9. Frew J, Wu X, Hsuing GY, HH Feldman, Mackenzie IR, Nygaard HB: Generation of an induced pluripotent stem cell line (UBCi001-A) from a presymptomatic individual carrying the R418X progranulin gene mutation. Stem Cell Res. 2019 Dec; 41:101582. Epub Nov 8. [PMID 31707213]

10. Boxer A, Gold M, Feldman HH, Boeve B, Dickinson S, Fillit H, Ho C, Paul R, Pearlman R, Sutherland M, Verma A, Arneric S, Alexander B: New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimers Dement. 2020 Jan 6. org/10.1016/j.jalz.2019.06.4956 [PMID 31668596]
11. Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H, Baker LD, Belleville S, Brodaty H, Brucki SM, Calandri I, Caramelli P, Chen C, Chertkow H, Chew E, Crivelli L, de La Torre, Espeland M, (Feldman HH), et al. World-Wide FINGERS Network: A Global Approach to Risk Reduction and Prevention of Dementia. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Accepted May 4, 2020. 
12. Frew J, Barabaran-Heravi A, Balgi AD, Wu XJ, Yan TD, Arns S, Shidmoossavee FS, Tan JS, Jaquith JB, Jansen-West KR, Lynn FC, Gao FB, Petrucelli L, Feldman HH, Mackenzie IR, Roberge M, Nygaard HB: Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. Mol Neurodegeneration15, 21 (2020). https://doi.org/10.1186/s13024-020-00369-5.
13. Weigand AJ, Bondi MW, Thomas KR, Campbell NL, Galasko DR, Salmon DP, Sewell D, Brewer JB, Feldman HH, Delano-Wood L.Association of anticholinergic medication and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology, 2020; doi: 10.1212/WNL.0000000000010643.
14. Funnell C, Feldman HH, Mackenzie IRA, DeMarco ML. Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. Alzheimer Dis Assoc Disord. 2020 Oct-Dec;34(4):357-359. doi: 10.1097/WAD.0000000000000372. PMID: 33215886. 
15. Chornenka K, Hirsch-Reinshagen V, Perez-Rosendahl M, Feldman HH, Segal-Gidan F, Vinters HV, Mackenzie IR: Expanding the phenotype of frontotemporal lobar degeneration with FUS-positive pathology (FTLD-FUS). J Neuropathol Exp Neurol. 2020;79(7):809-812. doi:10.1093/jnen/nlaa045. PMID: 32483606.
16. Banks SJ, Qiu Y, Fan CC, Dale AM, Zou J, Askew B, Feldman HH; Alzheimer’s Disease Neuroimaging Initiative. Enriching the design of Alzheimer’s disease clinical trials: Application of the polygenic hazard score and composite outcome measures. Alzheimers Dement (N Y). 2020 Sep 13;6(1):e12071. doi: 10.1002/trc2.12071. PMID: 32999917; PMCID: PMC7507583.
17. Jacobs DM, Thomas RG, Salmon DP, Jin S, Feldman HH, Cotman CW, Baker LD; Alzheimer’s Disease Cooperative Study EXERT Study Group; Alzheimer’s Disease Neuroimaging Initiative. Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS-Cog-Exec. Alzheimers Dement (N Y). 2020 Sep 9;6(1):e12059. doi: 10.1002/trc2.12059. PMID: 32995469; PMCID: PMC7507362.
18. Kent BA, Feldman HH, Nygaard HB. Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer’s disease. Prog Neurobiol. 2021 Feb;197:101902. doi: 10.1016/j.pneurobio.2020.101902. Epub 2020 Aug 30. PMID: 32877742; PMCID: PMC7855222.
19. Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C, Kinney JW, Tousi B, Leverenz JB, Fillit H, Zhong K, Feldman HH, Cummings J. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer’s dementia. Alzheimer’s Dement. 2021; 7:e12106. https://doi.org/10.1002/trc2.12106
20. Chu SA, Flagan TM, Staffaroni AM, Jiskoot LC, Deng J, Spina S, Zhang L, Sturm VE, Yokoyama JS, Seeley WW, Papma JM, Geschwind DH, Rosen HJ, Boeve BF, Boxer AL, Heuer HW, Forsberg LK, Brushaber DE, Grossman M, Coppola G, Dickerson BC, Bordelon YM, Faber K, Feldman HH…Lee SE. Brain volumetric deficits in MAPT mutation carriers: a multisite study. Ann Clin Transl Neurol. 2021 Jan;8(1):95-110. doi: 10.1002/acn3.51249. Epub 2020 Nov 28. PMID: 33247623; PMCID: PMC7818091.